A promising immunotherapy in breast cancer is the newly developed antibodies to programmed cell death ligand-1 (PD-L1) and cytotoxic T-lymphocytic associated protein 4 (CTLA-4) that interferes with robust immune surveillance and escape by exhausting T cells in the tumor microenvironment. Here, CTLA4 is linked to breast carcinoma.